Ovid Therapeutics (OVID) FCF Margin (2020 - 2025)
Ovid Therapeutics (OVID) reported FCF Margin of 1444.85% for Q4 2025, up 1168936.0% on a YoY basis from N/an in Q4 2024, and up 85.18% quarter-over-quarter from 9751.52% in Q3 2025.
Ovid Therapeutics (OVID) FCF Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics has reported FCF Margin for 6 years, with the latest figure at 1444.85% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin rose 1168936.0% year-over-year to 1444.85%; the trailing twelve-month figure through Mar 2026 stood at 588.58% (up 846634.0% YoY), and the FY2025 full-year result was 528.13%, up 937399.0% from the prior year.
- FCF Margin for Q4 2025 stood at 1444.85%, up from 9751.52% in the prior quarter.
- The five-year high for FCF Margin was 77.21% in Q1 2021, with the low at 106664.32% in Q3 2022.
- Historically, FCF Margin has averaged 15198.17% across 5 years, with a median of 8928.43% in 2023.
- The largest YoY upside for FCF Margin was 9751845 bps in 2023 against a maximum downside of 1613754 bps in 2023.
- Ovid Therapeutics' FCF Margin stood at 77.21% in 2021, then tumbled by 28501 bps to 21929.06% in 2022, then soared by 62 bps to 8397.18% in 2023, then tumbled by 56 bps to 13134.21% in 2024, then surged by 89 bps to 1444.85% in 2025.
- The last three FCF Margin figures came in at 1444.85% (Q4 2025), 9751.52% (Q3 2025), and 76.12% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,444.85% |
| Sep 30, 2025 | -9,751.52% |
| Jun 30, 2025 | -76.12% |
| Mar 31, 2025 | -7,907.69% |
| Dec 31, 2024 | -13,134.21% |
| Sep 30, 2024 | -8,710.98% |
| Jun 30, 2024 | -8,455.03% |
| Mar 31, 2024 | -11,287.16% |
| Dec 31, 2023 | -8,397.18% |
| Sep 30, 2023 | -9,145.87% |
| Jun 30, 2023 | -15,736.00% |
| Mar 31, 2023 | -18,372.73% |
| Dec 31, 2022 | -21,929.06% |
| Sep 30, 2022 | -106,664.32% |
| Mar 31, 2022 | -2,235.18% |
| Mar 31, 2021 | 77.21% |
| Dec 31, 2020 | -255.26% |
| Sep 30, 2020 | -24.26% |